Pharmaceutical

Valneva pushes FDA approval date for chikungunya vaccine

The PDUFA date has been pushed by three months to November to allow for more time for Phase IV activities.

Aug 14, 2023 - 20:00
Valneva pushes FDA approval date for chikungunya vaccine
The PDUFA date has been pushed by three months to November to allow for more time for Phase IV activities.
Read the original article

Tags:

Previous Article

LifeArc invests nearly $10m in Crick Institute’s Africa Scheme

Next Article

Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Q2 2024 update: electronic medical record (emr) systems related private equity activity in the pharmaceutical industry

Q2 2024 update: electronic medical record (emr) systems...

Aug 7, 2024

Pneumagen raises £8 million for further study of intranasal antiviral

Pneumagen raises £8 million for further study of intran...

Jun 1, 2023

STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer

STAT+: Allogene to pursue new strategy for development ...

Jan 4, 2024